(1COV) Covestro - Ratings and Ratios
Polyurethanes, Polycarbonates, MDI, Polyols, Elastomers
1COV EPS (Earnings per Share)
1COV Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 14.5% |
| Value at Risk 5%th | 20.4% |
| Relative Tail Risk | -14.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.13 |
| Alpha | 1.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.198 |
| Beta | -0.034 |
| Beta Downside | -0.002 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.76% |
| Mean DD | 4.62% |
| Median DD | 3.02% |
Description: 1COV Covestro October 31, 2025
Covestro AG (XETRA: 1COV) is a German specialty-chemicals group that supplies high-tech polymer materials and application solutions across two segments: Performance Materials, which produces polyurethanes, polycarbonates and base chemicals such as MDI and TDI for furniture, construction, automotive and insulation markets; and Solutions & Specialties, which offers polymer products, coating precursors, specialty films and elastomers used in automotive, electronics, construction, healthcare and renewable-energy applications. The company sells primarily through trading houses and distributors and operates globally in Europe, the Middle East, Africa, the Americas and China.
Key recent metrics (FY 2023) show revenue of roughly €16.5 billion, an adjusted EBITDA margin of about 12 % and R&D spending of €800 million, reflecting Covestro’s focus on high-value, lightweight and low-carbon-footprint polymers. The segment’s growth is driven by secular trends such as automotive lightweighting, stricter building-insulation regulations in Europe, and expanding demand for polymer components in electric-vehicle batteries and solar-panel frames. Capital-expenditure plans for 2024 target €1.2 billion to expand capacity in polycarbonate and TPU lines, aiming to capture the anticipated 4-5 % CAGR in the specialty-polymer market.
For a deeper, data-driven valuation of Covestro, the ValueRay platform provides the granular financial and market metrics needed to model its upside and downside scenarios.
1COV Stock Overview
| Market Cap in USD | 13,062m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | |
| Return 12m vs S&P 500 | -9.08% |
| Analyst Rating | - |
1COV Dividends
Currently no dividends paid1COV Growth Ratios
| CAGR 3y | 18.52% |
| CAGR/Max DD Calmar Ratio | 0.94 |
| CAGR/Mean DD Pain Ratio | 4.01 |
| Current Volume | 30.4k |
| Average Volume | 9.7k |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (-378.0m TTM) > 0 and > 6% of Revenue (6% = 830.1m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -1.07pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.52% (prev 18.17%; Δ -6.65pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 758.0m > Net Income -378.0m (YES >=105%, WARN >=100%) |
| Net Debt (-489.0m) to EBITDA (904.0m) ratio: -0.54 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (188.7m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 14.09% (prev 15.82%; Δ -1.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 101.8% (prev 101.0%; Δ 0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.59 (EBITDA TTM 904.0m / Interest Expense TTM 142.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.61
| (A) 0.12 = (Total Current Assets 5.64b - Total Current Liabilities 4.04b) / Total Assets 13.21b |
| (B) 0.15 = Retained Earnings (Balance) 2.03b / Total Assets 13.21b |
| (C) -0.01 = EBIT TTM -84.0m / Avg Total Assets 13.59b |
| (D) 0.34 = Book Value of Equity 2.41b / Total Liabilities 7.04b |
| Total Rating: 1.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.39
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield -0.81% = -0.40 |
| 3. FCF Margin -0.84% = -0.31 |
| 4. Debt/Equity 0.59 = 2.33 |
| 5. Debt/Ebitda -0.54 = 2.50 |
| 6. ROIC - WACC (= -5.42)% = -6.78 |
| 7. RoE -5.85% = -0.97 |
| 8. Rev. Trend -75.64% = -5.67 |
| 9. EPS Trend 24.11% = 1.21 |
What is the price of 1COV shares?
Over the past week, the price has changed by +2.00%, over one month by +0.53%, over three months by -0.66% and over the past year by +5.14%.
Is Covestro a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of 1COV is around 60.76 EUR . This means that 1COV is currently overvalued and has a potential downside of 0.96%.
Is 1COV a buy, sell or hold?
What are the forecasts/targets for the 1COV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.4 | 2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 65.3 | 8.5% |
1COV Fundamental Data Overview January 01, 1970
Market Cap EUR = 11.25b (11.25b EUR * 1.0 EUR.EUR)
P/E Forward = 36.2319
P/S = 0.8396
P/B = 1.8184
P/EG = 0.5107
Beta = 1.042
Revenue TTM = 13.84b EUR
EBIT TTM = -84.0m EUR
EBITDA TTM = 904.0m EUR
Long Term Debt = 1.84b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 1.55b EUR (from shortTermDebt, last quarter)
Debt = 3.66b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -489.0m EUR (from netDebt column, last quarter)
Enterprise Value = 14.34b EUR (11.25b + Debt 3.66b - CCE 566.0m)
Interest Coverage Ratio = -0.59 (Ebit TTM -84.0m / Interest Expense TTM 142.0m)
FCF Yield = -0.81% (FCF TTM -116.0m / Enterprise Value 14.34b)
FCF Margin = -0.84% (FCF TTM -116.0m / Revenue TTM 13.84b)
Net Margin = -2.73% (Net Income TTM -378.0m / Revenue TTM 13.84b)
Gross Margin = 14.09% ((Revenue TTM 13.84b - Cost of Revenue TTM 11.88b) / Revenue TTM)
Gross Margin QoQ = 16.34% (prev 13.37%)
Tobins Q-Ratio = 1.09 (Enterprise Value 14.34b / Total Assets 13.21b)
Interest Expense / Debt = 0.93% (Interest Expense 34.0m / Debt 3.66b)
Taxrate = 636.4% (out of range, set to none) (70.0m / 11.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.39 (Total Current Assets 5.64b / Total Current Liabilities 4.04b)
Debt / Equity = 0.59 (Debt 3.66b / totalStockholderEquity, last quarter 6.15b)
Debt / EBITDA = -0.54 (Net Debt -489.0m / EBITDA 904.0m)
Debt / FCF = 4.22 (negative FCF - burning cash) (Net Debt -489.0m / FCF TTM -116.0m)
Total Stockholder Equity = 6.47b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.86% (Net Income -378.0m / Total Assets 13.21b)
RoE = -5.85% (Net Income TTM -378.0m / Total Stockholder Equity 6.47b)
RoCE = -1.01% (EBIT -84.0m / Capital Employed (Equity 6.47b + L.T.Debt 1.84b))
RoIC = -0.98% (negative operating profit) (EBIT -84.0m / (Assets 13.21b - Curr.Liab 4.04b - Cash 566.0m))
WACC = 4.45% (E(11.25b)/V(14.91b) * Re(5.89%) + (debt cost/tax rate unavailable))
Discount Rate = 5.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -116.0m)
EPS Correlation: 24.11 | EPS CAGR: 533.0% | SUE: 0.24 | # QB: 0
Revenue Correlation: -75.64 | Revenue CAGR: -10.74% | SUE: -2.22 | # QB: 0